Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;43(5):1056-1067.
doi: 10.1111/liv.15542. Epub 2023 Feb 28.

Health-related quality of life in patients with primary sclerosing cholangitis: A longitudinal population-based cohort study

Bregje Mol  1 , Kim N van Munster  1 , Johannes A Bogaards  2 , Rinse K Weersma  3 , Akin Inderson  4 , E Joline de Groof  1 , Noortje G M Rossen  1 , Willemijn Ponsioen  1 , Maud Turkenburg  1 , Karel J van Erpecum  5 , Alexander C Poen  6 , B W Marcel Spanier  7 , Ulrich H W Beuers  1 , Cyriel Y Ponsioen  1 ; EpiPSC2 study group
Affiliations

Health-related quality of life in patients with primary sclerosing cholangitis: A longitudinal population-based cohort study

Bregje Mol et al. Liver Int. 2023 May.

Abstract

Background & aims: Data regarding health-related quality of life (HRQoL) in primary sclerosing cholangitis (PSC) are sparse and have only been studied cross-sectionally in a disease which runs a fluctuating and unpredictable course. We aim to describe HRQoL longitudinally by using repeated measurements in a population-based cohort.

Methods: Every 3 months from May 2017 up to August 2020, patients received digital questionnaires at home. These included the EQ-5D, 5-D Itch, patient-based SCCAI and patient-based HBI. The SF-36, measuring HRQoL over eight dimensions as well as a physical component summary (PCS) and mental component summary (MCS) score, was sent annually. Data were compared with Dutch reference data and a matched IBD disease control from the population-based POBASIC cohort. Mixed-effects modelling was performed to identify factors associated with HRQoL.

Results: Three hundred twenty-eight patients completed 2576 questionnaires. A significant reduction of small clinical relevance in several mean HRQoL scores was found compared with the Dutch reference population: 46.4 versus 48.0, p = .018 for PCS and 47.5 versus 50.5, p = .004 for MCS scores. HRQoL outcomes were significantly negatively associated with coexisting active IBD (PCS -12.2, p < .001 and MCS -12.0, p < .001), which was not the case in case of quiescent IBD. Decreasing HRQoL scores were also negatively associated with increasing age (PCS -0.1 per 10 years, p = .002), female sex (PCS -2.8, p < .001), diagnosis of AIH overlap (PCS -3.7, p = .059), end-stage liver disease (PCS -3.7, p = .015) and presence of itch (PCS -9.2, p < .001 and MCS -3.1, p = .078). The odds of reporting a clinically relevant reduction in EQ-5D scores showed seasonal variation, being lowest in summer (OR = 0.48 relative to spring, p = .037). In patients with liver transplant, HRQoL outcomes were comparable to the Dutch general population.

Conclusions: PSC patients report impaired HRQoL of small clinical relevance compared with the general population. After liver transplantation, HRQoL scores are at comparable levels to the general population. HRQoL scores are associated with potentially modifiable factors such as itch and IBD activity.

Keywords: health-related quality of life; inflammatory bowel disease; population-based cohort; post-transplant; primary sclerosing cholangitis; repeated measurements.

PubMed Disclaimer

References

REFERENCES

    1. Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. Primary sclerosing cholangitis. Lancet (London, England). 2018;391(10139):2547-2559.
    1. Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (Baltimore, Md). 2013;58(6):2045-2055.
    1. Marcus E, Stone P, Krooupa A-M, Thorburn D, Vivat B. Quality of life in primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes. 2021;19(1):100.
    1. Ponsioen CY, Lindor KD, Mehta R, Dimick-Santos L. Design and endpoints for clinical trials in primary Sclerosing cholangitis. Hepatology (Baltimore, Md). 2018;68(3):1174-1188.
    1. Europe PP. Survey Report PSCPE May 2017; 2017. https://www.pscpatientseurope.org/wp-content/uploads/2018/03/ReportPSCPE...

Publication types

LinkOut - more resources